Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine OVERALL - PROJECT SUMMARY This is the 3nd CCSG competitive renewal application of the Dan L Duncan Comprehensive Cancer Center (DLDCCC) at Baylor College of Medicine (BCM) in Houston, Texas. Houston is the 4th largest city in the United States with a very diverse population and Harris County is one of the most rapidly growing in the country. The DLDCCC Catchment Area has expanded from the core of Harris county to include the 8 surrounding counties which comprise the Houston Metropolitan Statistical Area (MSA), representing a diverse population of more than 7 million individuals (this population is greater than 35 states). The DLDCCC is a matrix center with BCM as the lead partner with 4 hospital affiliates, Texas Children?s, the DeBakey Veterans Affairs Medical Center, Ben Taub Hospital, and the new Baylor St. Luke?s Medical Center as formal affiliates. The DLDCCC received NCI designation in 2007 and comprehensive designation in 2014 and through our evaluation and planning process and recommendations from our EAC and internal committees, we have since made significant progress strengthening our scientific programs. 53 new cancer faculty have been recruited to the DLDCCC which now has 192 Research members, 78 Clinical members and 18 Adjunct members. Our cancer-relevant peer reviewed research funding now exceeds $169 million, with more than $49 million ($34M direct) coming from the NCI. Several important scientific accomplishments have been made that have an impact in our Catchment Area and globally. The DLDCCC comprises 7 research programs: Cell Signaling and Metabolism, Mechanism of Cancer Evolution, Nuclear Receptor, Transcription and Chromatin Biology, Breast Cancer, Cancer Cell and Gene Therapy, Cancer Prevention and Population Science, and Pediatric Cancer. Significant investments have strengthened the 10 Shared Resources, which offer leading technologies. A new shared resource in Advanced In Vivo Cancer Models further enhances our capabilities. The Clinical Protocol and Data Management Core has been significantly enhanced and accruals to clinical trials have increased. Accrual of racial and ethnic minorities is outstanding. The Office of Outreach and Health Disparities which drives COE disseminates new information and services to the community, especially the underserved. Training and education have been integrated into our Programs through the CRCE core. In this renewal, we ask for increased funding for our 10 Shared Resources and other expanded activities important to our mission and goals.

Public Health Relevance

Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine OVERALL - PROJECT NARRATIVE Cancer is a leading cause of morbidity and mortality in the United States and globally. The diagnosis and treatment of cancer are extraordinarily demanding and increasingly expensive with major impacts on our economy. Although overall survival from cancer has improved and certain cancers can be prevented or cured, much remains to be accomplished to improve patient outcome through research to develop novel strategies to prevent, diagnose early, and effectively treat this disease. The Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine has put together a strong multidisciplinary team of scientists, clinicians, educators, and community outreach experts to further improve survival from cancer both in our Catchment Area and globally, and to educate the scientists and clinicians of the future.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Baylor College of Medicine
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Szwarc, Maria M; Kommagani, Ramakrishna; Putluri, Vasanta et al. (2018) Steroid Receptor Coactivator-2 Controls the Pentose Phosphate Pathway through RPIA in Human Endometrial Cancer Cells. Sci Rep 8:13134
Kruse, Robert L; Shum, Thomas; Tashiro, Haruko et al. (2018) HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice. Cytotherapy 20:697-705
Samaha, Heba; Pignata, Antonella; Fousek, Kristen et al. (2018) A homing system targets therapeutic T cells to brain cancer. Nature 561:331-337
Disney-Hogg, Linden; Sud, Amit; Law, Philip J et al. (2018) Influence of obesity-related risk factors in the aetiology of glioma. Br J Cancer 118:1020-1027
Su, Jianzhong; Huang, Yung-Hsin; Cui, Xiaodong et al. (2018) Homeobox oncogene activation by pan-cancer DNA hypermethylation. Genome Biol 19:108
Lu, Lianghao; Wen, Yefei; Yao, Yuan et al. (2018) Glucocorticoids Inhibit Oncogenic RUNX1-ETO in Acute Myeloid Leukemia with Chromosome Translocation t(8;21). Theranostics 8:2189-2201
Martini-Stoica, Heidi; Cole, Allysa L; Swartzlander, Daniel B et al. (2018) TFEB enhances astroglial uptake of extracellular tau species and reduces tau spreading. J Exp Med 215:2355-2377
Wang, Changjun; Zaheer, Mahira; Bian, Fang et al. (2018) Sjögren-Like Lacrimal Keratoconjunctivitis in Germ-Free Mice. Int J Mol Sci 19:
Singh, Ramesh; Karri, Dileep; Shen, Hong et al. (2018) TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis. J Clin Invest 128:3129-3143
Mundt, Filip; Rajput, Sandeep; Li, Shunqiang et al. (2018) Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers. Cancer Res 78:2732-2746

Showing the most recent 10 out of 991 publications